|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
| Probably the biggest single driver for
any manufacturer in the pharmaceutical
industry has to be the time it takes to get a
potential product through the research and
development phases and out to market.
With R&D costs to bring a new drug to
release approximated at $1 million a day,
only when a product is in daily use does
the huge investment undertaken by drug
companies seeking the next blockbuster
product begin to pay back. There are plenty of examples, across
many industries, of companies being late
to market with a product, only to find
further down the line that competitors’
products have subsequently appeared,
with a resulting substantial hit in potential
operating profits. Once a company is
in the process of research... |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
New Report Uncovers the Extent of Data Integrity Challenges for UK Pharmaceutical Manufacturers
Big data, audit trails, system integration and access
privileges are among the most pressing data integrity challenges for
pharmaceutical manufacturers, according to a new industry report
published by Yokogawa.
With many
manufacturers already facing historical data integrity challenges,
including hybrid systems and ageing equipment, the advent of digital
transformation is set to place further pressure on manufacturers looking
to remain on the right side of auditors.
More info >> |
|
 |
White Papers |
 |
|
Smaller, Smarter, Electronic, Connected: The Next Generation of Drug-Delivery Devices
Phillips-Medisize
An exciting trend in drug delivery is underway: the movement toward smaller, smarter, wirelessly connected electronic devices that allow patient-administered therapy. Inspired by the technological advancements driving the consumer electronics market, new methods for drug delivery show great promise for all stakeholders. Patients wishing to claim more autonomy over their drug regimens, caregivers and medical professionals wanting to more closely monitor drug compliance, health insurance organizations looking to keep costs down, and developers of pharmaceutical products interested in conducting better managed
clinical trials can all benefit from these novel, next-generation technologies.
More info >> |
|
|
